Life sciences companies confront increasingly stringent requirements on safety signal detection and risk management. Regulatory authorities are taking steps to further safeguard patients by requiring companies to take more comprehensive steps to assess and monitor the benefit-risk balance of their products.
Our first blog on this topic addressed “The importance of mobility and medical affairs (MA) and its value to the organization is most definitely on the rise.” In this concluding blog we share specific examples of how mobile technology improves MA and arms you with the criteria and questions to ask as you investigate possible medical information solutions.
Change is the lone constant you can depend on. When ...
During a recent webcast, ArisGlobal carried out an insightful survey, which found that visibility and reporting inefficiencies remain a headache.
For many companies, signal detection in drug safety pharmacovigilance ranks closely behind regulatory submissions and case management as a key activity because it helps to proactively monitor a product’s risks that come to light from tracking the data submitted to internal and external drug safety databases and platforms.
Keeping track of all the information required to manage your ...
In the ever-evolving landscape of data management, the life sciences ...
ArisGlobal Announces the Launch of LifeSphere Clarity As a pharmacovigilance ...
It’s hard to think about COVID-19 and vaccine production, without ...
Moving to a structured content authoring approach presents the challenge of ensuring that data and documents are in sync. So where do life sciences organizations stand today in this transformation phase? Wim Cypers, Senior VP, Regulatory, shares his insights from our recent webinar.
Quick Links
Follow Us
© 2024 ArisGlobal – All Rights Reserved
